Hence, targeting the C5– C5aR1–GCS glycosphingolipid pathway could protect the SARS-CoV-2-induced development of s severe form of the disease in patients with COVID-19 and GD patients with COVID-19. The gene discussed is C5; the disease is COVID-19.